Possible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disorders

Medical Hypotheses

Volumn 93, Issue , 2016, Pages 161-165

  Lakkappa, Navya ^a   Krishnamurthy, Praveen T ^a   Hammock, Bruce D ^b   Velmurugan, D ^c   Bharath, M M Srinivas ^d  

^a JSS COLLEGE OF PHARMACY   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MADRAS   (India)

^d NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Apoptosis; Cytochrome P450; EETs; Neuroinflammation; Neuroprotection; Oxidative stress; PD; sEH

Indexed keywords

CALCIUM ION; CASPASE 3; CASPASE 9; EPOXYICOSATRIENOIC ACID; GLUTATHIONE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; VANILLOID RECEPTOR 1; ARACHIDONIC ACID; ARACHIDONIC ACID DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CELL PROTECTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DRUG HALF LIFE; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; INTRACELLULAR SIGNALING; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA; ANIMAL; CHEMISTRY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HYPERTENSION; INFLAMMATION; METABOLISM; MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION; SOLUBILITY; THEORETICAL MODEL;

ANIMALS; APOPTOSIS; ARACHIDONIC ACID; ARACHIDONIC ACIDS; CYTOPROTECTION; DOPAMINERGIC NEURONS; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMANS; HYPERTENSION; INFLAMMATION; MICE; MODELS, THEORETICAL; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; SOLUBILITY;

EID: 84978888887     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2016.06.003     Document Type: Article

References (69)

1. [1] Tanner, C.M., Goldman, S.M., Epidemiology of Parkinson's disease. Neurol Clin 14 (1996), 317–335.
2. [2] de Lau, L.M., Breteler, M.M., Epidemiology of Parkinson's disease. Lancet Neurol 5 (2006), 525–535.
3. [3] Chen, S.-Y., Tsai, S.-T., The epidemiology of Parkinson's disease. Tzu Chi Med J 22 (2010), 73–81.
4. [4] Hague, S., Klaffke, S., Bandmann, O., Neurodegenerative disorders: Parkinson's disease and Huntington's disease. J Neurol Neurosurg Psychiatry 76 (2005), 1058–1063.
5. [5] Reeve, A., Simcox, E., Turnbull, D., Ageing and Parkinson's disease: why is advancing age the biggest risk factor?. Ageing Res Rev 14 (2014), 19–30.
6. [6] Hindle, J.V., Ageing, neurodegeneration and Parkinson's disease. Age Ageing 39 (2010), 156–161.
7. [7] Antony, P., Diederich, N.J., Krüger, R., Balling, R., The hallmarks of Parkinson's disease. FEBS J 280 (2013), 5981–5993.
8. [8] Crosiers, D., Theuns, J., Cras, P., Van Broeckhoven, C., Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. J Chem Neuroanat 42 (2011), 131–141.
9. [9] und Halbach, O.V.B., Schober, A., Krieglstein, K., Genes, proteins, and neurotoxins involved in Parkinson's disease.Prog Neurobiol., 73, 2004, 151–177.
10. [10] Eriksen, J.L., Wszolek, Z., Petrucelli, L., Molecular pathogenesis of Parkinson disease. Arch Neurol 62 (2005), 353–357.
11. [11] Bonnet, A., Houeto, J., Pathophysiology of Parkinson's disease. Biomed Pharmacother 53 (1999), 117–121.
12. [12] Fernandez-Espejo, E., Pathogenesis of Parkinson's disease. Mol Neurobiol 29 (2004), 15–30.
13. [13] Ambhore, N., Mali, J., Kanhed, A., Antony, S., Bhalerao, A., Bhojraj, S., Pharmacological and biochemical interventions of cigarette smoke, alcohol, and sexual mating frequency on idiopathic rat model of Parkinson's disease. J Young Pharm 4 (2012), 177–183.
14. [14] Dalfó, E., Portero-Otín, M., Ayala, V., Martínez, A., Pamplona, R., Ferrer, I., Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64 (2005), 816–830.
15. [15] Forno, L.S., Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55 (1996), 259–272.
16. [16] Lee, H.-J., Bazinet, R.P., Rapoport, S.I., Bhattacharjee, A.K., Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease. Neurochem Res 35 (2010), 613–619.
17. [17] Samuelsson, B., An elucidation of the arachidonic acid cascade. Drugs 33 (1987), 2–9.
18. [18] Falck, J., Kodela, R., Manne, R., et al. 14,15-Epoxyeicosa-5,8,11-trienoic acid (14, 15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J Med Chem 52 (2009), 5069–5075.
19. [19] Marowsky, A., Burgener, J., Falck, J., Fritschy, J.-M., Arand, M., Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Neuroscience 163 (2009), 646–661.
20. [20] Sura, P., Sura, R., EnayetAllah, A.E., Grant, D.F., Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem 56 (2008), 551–559.
21. [21] Iliff, J.J., Jia, J., Nelson, J., Goyagi, T., Klaus, J., Alkayed, N.J., Epoxyeicosanoid signaling in CNS function and disease. Prostaglandins Other Lipid Mediat 91 (2010), 68–84.
22. [22] Shen, H.C., Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin Ther Pat 20 (2010), 941–956.
23. [23] Jiang, H., Anderson, G.D., McGiff, J.C., The red blood cell participates in regulation of the circulation by producing and releasing epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 98 (2012), 91–93.
24. [24] Khan, M.A.H., Pavlov, T.S., Christain, S.V., et al. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci 127 (2014), 463–474.
25. [25] Shrestha, A., Krishnamurthy, P.T., Thomas, P., Hammock, B.D., Hwang, S.H., Soluble epoxide hydrolase inhibitor, t-TUCB, protects against myocardial ischaemic injury in rats. J Pharm Pharmacol 66 (2014), 1251–1258.
26. [26] Qiu, H., Li, N., Liu, J.Y., Harris, T.R., Hammock, B.D., Chiamvimonvat, N., Soluble epoxide hydrolase inhibitors and heart failure. Cardiovasc Ther 29 (2011), 99–111.
27. [27] Huang, H., Chen, J., Lin, T., et al. Epoxyeicosatrienoic acids – novel mechanism and pharmacological therapy of chronic renocardiac syndrome. Med Hypotheses 76 (2011), 550–552.
28. [28] Lee, K.S.S., Liu, J.-Y., Wagner, K.M., et al. Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem 57 (2014), 7016–7030.
29. [29] Wagner, K., Yang, J., Inceoglu, B., Hammock, B.D., Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. J Pain 15 (2014), 907–914.
30. [30] Zhang, G., Panigrahy, D., Hwang, S.H., et al. Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc Natl Acad Sci 111 (2014), 11127–11132.
31. [31] López-Vicario, C., Alcaraz-Quiles, J., García-Alonso, V., et al. Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides. Proc Natl Acad Sci 112 (2015), 536–541.
32. [32] Zhang, W., Koerner, I.P., Noppens, R., et al. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 27 (2007), 1931–1940.
33. [33] Xu, X., Zhang, X.A., Wang, D.W., The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev 63 (2011), 597–609.
34. [34] Nithipatikom, K., Gross, G.J., Epoxyeicosatrienoic acids: novel mediators of cardioprotection. J Cardiovasc Pharmacol Ther, 2010.
35. [35] Yang, B., Graham, L., Dikalov, S., et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 60 (2001), 310–320.
36. [36] Iliff, J.J., Alkayed, N.J., Soluble epoxide hydrolase inhibition: targeting multiple mechanisms of ischemic brain injury with a single agent. Future Neurol 4 (2009), 179–199.
37. [37] Spector, A.A., Norris, A.W., Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol-Cell Physiol 292 (2007), C996–C1012.
38. [38] Spiecker, M., Liao, J.K., Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 433 (2005), 413–420.
39. [39] Qin, X., Wu, Q., Lin, L., et al. Soluble epoxide hydrolase deficiency or inhibition attenuates MPTP-induced parkinsonism. Mol Neurobiol, 2014, 1–9.
40. 2-induced cell injury in Astrocyte-dopaminergic neuronal cell line co-culture. Neuroscience, 223, 2012, 68.
41. [41] Hammock, B.D., Wagner, K., Inceoglu, B., The soluble epoxide hydrolase as a pharmaceutical target for pain management. Pain Manage 1 (2011), 383–386.
42. [42] Smith, K.R., Pinkerton, K.E., Watanabe, T., Pedersen, T.L., Ma, S.J., Hammock, B.D., Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 102 (2005), 2186–2191.
43. [43] Inceoglu, B., Jinks, S.L., Schmelzer, K.R., Waite, T., Kim, I.H., Hammock, B.D., Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci 79 (2006), 2311–2319.
44. [44] Schmelzer, K.R., Kubala, L., Newman, J.W., Kim, I.-H., Eiserich, J.P., Hammock, B.D., Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 102 (2005), 9772–9777.
45. [45] Yacoubian, T.A., Standaert, D.G., Targets for neuroprotection in Parkinson's disease.Biochim Biophys Acta (BBA) – Mol Basis Dis., 1792, 2009, 676–687.
46. [46] Alam, Z., Jenner, A., Daniel, S., et al. Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69 (1997), 1196–1203.
47. [47] Dexter, D., Sian, J., Rose, S., et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35 (1994), 38–44.
48. [48] Zhang, G., Kodani, S., Hammock, B.D., Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. Prog Lipid Res 53 (2014), 108–123.
49. [49] Liu, L., Chen, C., Gong, W., et al. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther 339 (2011), 451–463.
50. [50] Hirsch, E.C., Hunot, S., Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 8 (2009), 382–397.
51. [51] Zhang, W., Wang, T., Pei, Z., et al. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19 (2005), 533–542.
52. [52] Ghosh, A., Roy, A., Liu, X., et al. Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci 104 (2007), 18754–18759.
53. [53] Node, K., Huo, Y., Ruan, X., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 (1999), 1276–1279.
54. [54] Williams, L., Bradley, L., Smith, A., Foxwell, B., Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 172 (2004), 567–576.
55. [55] Venkatachalam, K., Montell, C., TRP channels. Annu Rev Biochem, 76, 2007, 387.
56. [56] Pasceri, V., Wu, H.D., Willerson, J.T., Yeh, E.T., Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101 (2000), 235–238.
57. [57] Zhao, J.-F., Ching, L.-C., Kou, Y.R., et al. Activation of TRPV1 prevents OxLDL-induced lipid accumulation and TNF-α-induced inflammation in macrophages: role of liver X receptor α. Mediators Inflamm, 2013, 2013.
58. [58] Liu, Y., Zhang, Y., Schmelzer, K., et al. The antiinflammatory effect of laminar flow: the role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 102 (2005), 16747–16752.
59. [59] Swanson, C.R., Du, E., Johnson, D.A., Johnson, J.A., Emborg, M.E., Neuroprotective properties of a novel non-thiazoledinedione partial PPAR-γ agonist against MPTP. PPAR Res, 2013, 2013.
60. [60] Kannurpatti, S.S., Joshi, P.G., Joshi, N.B., Calcium sequestering ability of mitochondria modulates influx of calcium through glutamate receptor channel. Neurochem Res 25 (2000), 1527–1536.
61. [61] Surmeier, D.J., Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 6 (2007), 933–938.
62. [62] Chen, J., Capdevila, J.H., Zeldin, D.C., Rosenberg, R.L., Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 55 (1999), 288–295.
63. [63] Ilijic, E., Guzman, J., Surmeier, D., The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis 43 (2011), 364–371.
64. [64] Strauss, K.I., Gruzdev, A., Zeldin, D.C., Altered behavioral phenotypes in soluble epoxide hydrolase knockout mice: effects of traumatic brain injury. Prostaglandins Other Lipid Mediat 104 (2013), 18–24.
65. [65] Qin, X., Wu, Q., Lin, L., et al. Soluble epoxide hydrolase deficiency or inhibition attenuates MPTP-induced parkinsonism. Mol Neurobiol 52 (2015), 187–195.
66. [66] Abdu, E., Bruun, D.A., Yang, D., et al. Epoxyeicosatrienoic acids enhance axonal growth in primary sensory and cortical neuronal cell cultures. J Neurochem 117 (2011), 632–642.
67. [67] Munzenmaier, D.H., Harder, D.R., Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol – Heart Circ Physiol 278 (2000), H1163–H1167.
68. [68] Wang, Y., Wei, X., Xiao, X., et al. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 314 (2005), 522–532.
69. [69] Sellers, K.W., Sun, C., Diez-Freire, C., et al. Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB J 19 (2005), 626–628.